Richard A Deyo1,2,3,4, Jessica M Irvine4, Sara E Hallvik4, Christi Hildebran4, Todd Beran5, Lisa M Millet5, Miguel Marino1,3. 1. Departments of Family Medicine. 2. Internal Medicine. 3. Public Health and Preventive Medicine, Center for Research in Occupational and Environmental Toxicology, Oregon Health and Science University. 4. Acumentra Health. 5. Public Health Division of the Oregon Health Authority, Portland, OR.
Abstract
OBJECTIVES: Prescription Drug Monitoring Programs (PDMPs) can help inform patient management, coordinate care, and identify drug safety risks, abuse, or diversion. However, many clinicians are not registered to use these systems, and use may be suboptimal. We sought to describe outreach efforts in 1 state (Oregon); quantify uptake of system use; identify barriers; and identify potential system improvements. METHODS: Program reports of outreach efforts and operational metrics provided rates of registration and use. A statewide survey identified perceived barriers and potential improvements from users and nonusers of the system. RESULTS: Even with extensive registration efforts, <25% of clinicians and pharmacists acquired PDMP accounts over 2 years of operation. Rapid increases in registration and use in 2013 corresponded to new requirements among large pharmacy chains that pharmacists register for and use the PDMP. Among surveyed PDMP nonusers, nearly half were unaware that they could register. Among users and nonusers, over two thirds indicated that time constraints were a major barrier and over half thought that inability to delegate access was a major barrier. Desired improvements included linking state systems, faster entry of pharmacy data, and use of unique patient identifiers. Users also wanted better insurance coverage for mental health and addiction referrals. DISCUSSION: Increasing registration and use of PDMPs remains important. Clinician feedback indicates that program enhancements and health care system changes would facilitate using and responding to PDMP information. It appears premature to judge the efficacy of PDMPs until best practices for their use are identified and impacts are assessed.
OBJECTIVES: Prescription Drug Monitoring Programs (PDMPs) can help inform patient management, coordinate care, and identify drug safety risks, abuse, or diversion. However, many clinicians are not registered to use these systems, and use may be suboptimal. We sought to describe outreach efforts in 1 state (Oregon); quantify uptake of system use; identify barriers; and identify potential system improvements. METHODS: Program reports of outreach efforts and operational metrics provided rates of registration and use. A statewide survey identified perceived barriers and potential improvements from users and nonusers of the system. RESULTS: Even with extensive registration efforts, <25% of clinicians and pharmacists acquired PDMP accounts over 2 years of operation. Rapid increases in registration and use in 2013 corresponded to new requirements among large pharmacy chains that pharmacists register for and use the PDMP. Among surveyed PDMP nonusers, nearly half were unaware that they could register. Among users and nonusers, over two thirds indicated that time constraints were a major barrier and over half thought that inability to delegate access was a major barrier. Desired improvements included linking state systems, faster entry of pharmacy data, and use of unique patient identifiers. Users also wanted better insurance coverage for mental health and addiction referrals. DISCUSSION: Increasing registration and use of PDMPs remains important. Clinician feedback indicates that program enhancements and health care system changes would facilitate using and responding to PDMP information. It appears premature to judge the efficacy of PDMPs until best practices for their use are identified and impacts are assessed.
Authors: Traci C Green; Marita R Mann; Sarah E Bowman; Nickolas Zaller; Xaviel Soto; John Gadea; Catherine Cordy; Patrick Kelly; Peter D Friedmann Journal: Pain Med Date: 2012-07-30 Impact factor: 3.750
Authors: Jessica M Irvine; Sara E Hallvik; Christi Hildebran; Miguel Marino; Todd Beran; Richard A Deyo Journal: J Pain Date: 2014-04-29 Impact factor: 5.820
Authors: Richard A Deyo; Jessica M Irvine; Lisa M Millet; Todd Beran; Nicole O'Kane; Dagan A Wright; Dennis McCarty Journal: Health Aff (Millwood) Date: 2013-02-13 Impact factor: 6.301
Authors: Matthew J Witry; Barbara J St Marie; Brahmendra Reddy Viyyuri; Paul D Windschitl Journal: Pain Manag Nurs Date: 2019-05-24 Impact factor: 1.929
Authors: Jenna L McCauley; J Madison Hyer; V Ramesh Ramakrishnan; Renata Leite; Cathy L Melvin; Roger B Fillingim; Christie Frick; Kathleen T Brady Journal: J Am Dent Assoc Date: 2016-04-05 Impact factor: 3.634
Authors: Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Eve Dexter; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet Journal: J Gen Intern Med Date: 2016-08-02 Impact factor: 5.128
Authors: Marcus A Bachhuber; Brendan Saloner; Marc LaRochelle; Jessica S Merlin; Brandon C Maughan; Dan Polsky; Naum Shaparin; Sean M Murphy Journal: Pain Med Date: 2018-10-01 Impact factor: 3.750
Authors: Gillian J Leichtling; Jessica M Irvine; Christi Hildebran; Deborah J Cohen; Sara E Hallvik; Richard A Deyo Journal: Pain Med Date: 2017-06-01 Impact factor: 3.750
Authors: Jenna L McCauley; Renata S Leite; Valeria V Gordan; Roger B Fillingim; Gregg H Gilbert; Cyril Meyerowitz; David Cochran; D Brad Rindal; Kathleen T Brady Journal: J Am Dent Assoc Date: 2018-03-15 Impact factor: 3.634
Authors: Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Rachel Springer; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet; Jody Carson; Wayne Wakeland; Dennis McCarty Journal: J Pain Date: 2017-10-18 Impact factor: 5.820
Authors: Jenna L McCauley; Renata S Leite; Cathy L Melvin; Roger B Fillingim; Kathleen T Brady Journal: Subst Abus Date: 2015-12-16 Impact factor: 3.716